Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 5, 2007, Pages 503-507

  Harenberg, Job ^a   Giese, Christina ^a   Hagedorn, Antje ^a   Traeger, Inge ^a   Fenyvesi, Tivadar ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

And melagatran; Argatroban; Fondaparinux; Hirudin; Idraparinux; Prothrombinase induced clotting time

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CHROMOGENIC SUBSTRATE; DALTEPARIN; FONDAPARINUX; HEPARIN DERIVATIVE; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; THROMBIN INHIBITOR;

ANTICOAGULATION; BLOOD CLOTTING TIME; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HUMANS; OLIGOSACCHARIDES; POLYSACCHARIDES; PROTHROMBIN; THROMBOPLASTIN;

EID: 34547091938     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-982081     Document Type: Conference Paper

References (16)

1. Van den Besselaar AM, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990; 63:16-23
2. Kher A, Gouin I, Samama MM. Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time. Ann Biol Clin (Paris) 2000;58:575-579 [in French]
3. Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996;75:734-739
4. Hirsh J, Rasdike R. Heparin and low-molecular-weight heparin. The Seventh ACLP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):1885-2035
5. Harenberg J, Giese Ch, Knödler A, Zimmermann R. Comparative study on a new one-stage clotting assay for heparin and its low-molecular-weight derivates. Haemostasis 1989;19:13-20
6. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost 1996;22:197-202
7. Calatzis A, Spannagl M, Gempeler-Messina P, et al. The prothrombinase-induced clotting time, a new technique for the monitoring of anticoagulants. Haemostasis 2000; 30(suppl 2):172-174
8. Schoni R. The use of snake-venom derived compounds for new functional diagnostic test kits in the field of haemostasis. Pathophysiol Haemost Thromb 2005;34:234-240
9. Fenyvesi T, Jörg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb 2002;32:174-179
10. Hyers TM, Agnelli G, Hull R, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998;114(3 suppl): S561-S578
11. Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huismann MV, Büller HRand the EASTERN Investigators. Fixed-dose, body weight-independent subcutaneous LMW-heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. Thromb Haemost 2000;83:652-656
12. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662
13. Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688-698
14. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-1828
15. Fenyvesi T, Joerg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002;28:361-368
16. Graff J, Picard-Willems B, Harder S. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther 2007;45:237-243